Shelly buys HTWR 54.13: Valtech provides HeartWare with commercial-stage products for mitral repair, as well as a robust technology pipeline, an advanced R&D center and an impressive, experienced team with a proven track record.

It is from this vantage point that we have concluded that Valtech's platforms represent the most innovative and comprehensive portfolio of interventional and surgical products for mitral and tricuspid repair and replacement in development today. TR is estimated to affect 1.6 million patients in the U.S. and complements the mitral patient population, as a significant percentage of patients suffer from both MR and TR. Approximately 4.2 million patients are affected by mitral valve disease in the U.S., which represents a several-billion-dollar market opportunity. Left untreated, severe MR can eventually lead to a meaningful deterioration in cardiac function and, eventually, death. MR is a condition in which the mitral valve leaflets fail to close properly, allowing backflow of blood from the left ventricle into the left atrium during systole.


Camilla:
HEARTWARE, HVAD, MVAD, PAL, SYNERGY, CIRCULITE and HeartWare logos are trademarks of HeartWare, Inc. or its affiliates.  VALTECH, CARDIOBAND, CARDINAL, CARDIOVALVE, V-CHORDAL and Valtech logos are trademarks of Valtech Cardio, Ltd.

Cicely:
The company, comprised of multidisciplinary development teams, works in close collaboration with world-renowned heart specialists to provide the best possible therapy for mitral patients.

Leatrice:
Valtech Cardio has full, in-house development, manufacturing, and clinical research capabilities, and over 130 patents and patent applications.

Jenifer:
We believe this portfolio positions HeartWare to deliver accelerated revenue growth and attractive shareholder returns over time.

Elisabeth:
HeartWare plans to lead the commercialization of the Valtech product portfolio, while maintaining Valtech as a separate business unit.

Alycia:
Valtech's product platforms align with HeartWare's strategic objective of delivering transformative, less-invasive therapies for patients with chronic heart failure.

Kathrine:
The acquisition accelerates and expands HeartWare's ability to deliver transformative technologies to patients and customers with a range of innovative VAD and valve therapies, leveraging the clinical overlap of the heart teams performing these procedures.

Eloisa:
This acquisition provides HeartWare with multiple, innovative, new, commercial opportunities in the significantly underserved areas of mitral and tricuspid valve diseases, from which many VAD patients today also suffer.

Tabetha:
The CardioValve platform has an orientation-indifferent structure for reduced implant complexity, was designed from inception to enable transseptal delivery, and can also be delivered transapically.

Rubie:
To date, Cardinal has been used to treat more than 75 patients globally.

Heartware International (NASDAQ:HTWR)
//stockhand.net/us/?q=nasdaq%3Ahtwr&id=358642